Editas Medicine, Inc.

EDIT · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.2%

Institutions79.2%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$160.01M	-$251.15M	-$169.18M	-$225.95M	-$193.15M	-$134.84M	-$140.92M	-$113.73M	-$119.93M	-$97.19M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$160.10M	-$237.09M	-$153.22M	-$220.43M	-$191.50M	-$115.98M	-$133.75M	-$109.95M	-$120.32M	-$97.18M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.00	$-2.00	$-2.00	$-3.00	$-2.85	$-1.98	$-2.00	$-2.33	$-2.00	$-3.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.00	$-2.00	$-2.00	$-3.00	$-2.83	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$146.65M	$131.54M	$123.65M	$141.52M	$203.52M	$139.68M	$238.18M	$134.78M	$146.63M	$185.32M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$186.53M	$341.59M	$499.15M	$514.32M	$677.48M	$572.60M	$508.88M	$420.39M	$373.26M	$229.18M
All of the company's interest-bearing borrowings, short and long term combined.	$58.60M	$57.43M	–	–	–	–	–	–	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$159.25M	$207.31M	$150.06M	$153.64M	$123.84M	$179.02M	$246.45M	$184.22M	$165.18M	$94.58M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$27.29M	$134.27M	$349.10M	$360.68M	$553.64M	$393.59M	$262.44M	$236.16M	$208.08M	$134.61M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$165.24M	-$210.28M	-$132.18M	-$177.35M	-$163.80M	-$179.84M	-$40.67M	-$45.71M	-$9.42M	-$49.93M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$607000	$8.83M	$4.72M	$4.12M	$7.98M	$7.16M	$6.17M	$4.75M	$2.06M	$3.49M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$165.85M	-$219.11M	-$136.90M	-$181.47M	-$171.78M	-$187.00M	-$46.84M	-$50.46M	-$11.48M	-$53.42M

	You	Peer avg
Revenue Growth	+232.3%	+857.3%
ROE	-118.8%	-203.1%

Editas Medicine, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison